Navigation Links
Hospira Announces U.S. Approval of Generic Docetaxel
Date:3/9/2011

LAKE FOREST, Ill., March 9, 2011 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval of docetaxel. The medication is a generic version of Sanofi-Aventis's Taxotere®, and Hospira expects to launch the product later this month.

Hospira's docetaxel is approved for the treatment of a variety of cancers. In 2010, U.S. sales of Taxotere were approximately $1.2 billion.

Unlike original product formulations that require healthcare workers to take a two-step process prior to infusion, Hospira's docetaxel comes in a single-vial formulation that is designed to reduce the number of handling steps in the preparation of the product.

"Hospira's docetaxel will give U.S. cancer patients access to a high-quality, lower-cost alternative to the branded product, offers a differentiated delivery system designed to enhance caregiver safety, and reinforces Hospira's commitment to meet patient and caregiver needs in the oncology space," said Thomas Moore, president, U.S., Hospira.

Hospira will offer 20 mg, 80 mg and 160 mg vials of docetaxel at a 10 mg/mL concentration, the original concentration that customers have used safely for many years. Hospira already markets docetaxel in Europe and Australia.

Hospira's specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. In addition, many of its products are available in popular differentiated presentations, several of which are proprietary, such as ADD-Vantage™ drug delivery system and iSecure™ prefilled syringes. Therapeutic segments include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, emergency and other areas. Hospira also has robust pipelines of both generic and biosimilar drugs.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at www.hospira.com.

Private Securities Litigation Reform Act of 1995 --

A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the growth opportunities for generic specialty injectable products. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, legal, regulatory, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira Board Names F. Michael Ball New CEO; Christopher B. Begley to Assume Executive Chairman Role
2. Hospira MedNet™ Portal Safety Software Benchmarking System Debuts at HIMSS
3. Hospira to Present at Upcoming Investor Conferences
4. Hospira Announces FDA Approval of Topotecan Injection
5. Hospira Reports Fourth-Quarter and Full-Year 2010 Results
6. Hospira to Host Conference Call for Fourth-Quarter 2010 Results and 2011 Projections
7. Hospira Launches Piperacillin and Tazobactam for Injection in the United States
8. Hospira Announces New Contracts in Effect with Novation for Infusion Pumps, Solutions and Equipment
9. Hospira to Host Conference Call for Third-Quarter 2010 Results
10. Hospira Receives TGA Approval for Nivestim™, Australias First Biosimilar Filgrastim
11. Hospira Japan Receives Approval for New Indication for Precedex IV™ 200ug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
(Date:9/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... on Friday, November 3, 2017, beginning at 7:00 a.m. ... 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... and guidance for 2018, Hill-Rom executives will also highlight ... and long-range financial outlook through 2020. ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the Law ... organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our ... a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
Breaking Medicine News(10 mins):